 ORIC and Pfizer have entered into a clinical development collaboration for a Phase 2 study of ORIC-533 in combination with elranatamab in multiple myeloma Jeff Settleman, Ph.D., Chief Scientific Officer, Pfizer Oncology, to join ORIC Scientific Advisory Board Including 25 million equity investment from Pfizer, ORIC cash runway extended into 1H 2025 SOUTH SAN FRANCISCO, ... The post ORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for ORIC-533 in Multiple Myeloma and... 